• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 8, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New incubator model for CSHL spin-outs

Bioengineer by Bioengineer
September 6, 2025
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Cold Spring Harbor Laboratory (CSHL) is collaborating with Autobahn Labs, a new life sciences incubator, to catalyze the Laboratory’s early-stage discovery programs into spin-out companies that commercialize transformational new therapies. CSHL is a world leader in basic biological research and in target discovery for human genetic diseases like cancer. Autobahn will provide up to $5 million to early-stage drug discovery projects that are beyond the academic funding model through its association with Samsara BioCapital, a leading life sciences investment firm and Evotec SE, a global drug discovery and development company.

“Autobahn has the ability to get involved early, put their resources into CSHL’s drug discovery programs, and generate a pipeline of highly investable spin-out companies,” said Andrew Whiteley, CSHL vice president of Business Development and Technology Transfer. “This collaboration will enable us to advance our basic biology expertise more quickly from the lab to the clinic.”

The collaboration is essential for continuing research projects with significant therapeutic potential by providing financial backing when academic research funds are no longer sufficient. Autobahn Labs’ $5 million per project investment will create jointly owned companies, offer operational and scientific expertise to guide drug development by way of Autobahn’s advisory group, and provide access to Evotec’s powerful drug discovery and drug development platforms. Autobahn’s executive team and advisors also add intellectual capital, with a wealth of expertise in launching successful therapeutic companies. “CSHL welcomes Autobahn’s innovative funding model as part of our high-value business development strategies for early-stage translational opportunities,” Whiteley explained.

Autobahn has the option to license successful technology from CSHL and move a company forward for a traditional Series A round of funding led by Samsara BioCapital. Together, CSHL’s scientists, Autobahn Labs, and Evotec will collaborate on advancing these programs.

###

Media Contact
Dagnia Zeidlickis
zeidlick@cshl.edu

Tags: BiologyBusiness/EconomicscancerCollaborationMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Two Retinal Emboli, Two Behaviors: One Migrated While Vision Spontaneously Returned

Two Retinal Emboli, Two Behaviors: One Migrated While Vision Spontaneously Returned

November 8, 2026
Review Highlights Exercise-Responsive Non-coding RNAs as Biomarkers in Neurodegenerative Diseases

Review Highlights Exercise-Responsive Non-coding RNAs as Biomarkers in Neurodegenerative Diseases

November 8, 2026

Surgical Review Reconsiders Routine Spleen Removal for Scirrhous Gastric Cancer

November 8, 2026

Hospital Study Reveals Gaps in Diabetic Foot Self-Care Knowledge in Ethiopia

November 8, 2026
Please login to join discussion

POPULAR NEWS

  • Surgical Review Reconsiders Routine Spleen Removal for Scirrhous Gastric Cancer

    Surgical Review Reconsiders Routine Spleen Removal for Scirrhous Gastric Cancer

    29 shares
    Share 12 Tweet 7
  • Hospital Study Reveals Gaps in Diabetic Foot Self-Care Knowledge in Ethiopia

    29 shares
    Share 12 Tweet 7
  • Electroacupuncture Protects Heart via SDF-1α Signaling

    29 shares
    Share 12 Tweet 7
  • Hip Exoskeleton Robot Enhances Walking Distance and Speed After Stroke in Trial

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Two Retinal Emboli, Two Behaviors: One Migrated While Vision Spontaneously Returned

Review Highlights Exercise-Responsive Non-coding RNAs as Biomarkers in Neurodegenerative Diseases

Surgical Review Reconsiders Routine Spleen Removal for Scirrhous Gastric Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.